Low level of adiponectin in the blood of patients with PE was found to be associated with endothelial dysfunction [93] and placental disorders; this may support further clinical use of adiponectin as a biomarker, therapeutic target, or therapeutic agent against the disease [94]. The gene discussed is ADIPOQ; the disease is placenta disorder.